GW PHARMACEUTICALS PLC November 24, 2015
LONDON, Nov. 24, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ('GW' or 'the Company'), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, will present at the Piper Jaffray 27th Annual Healthcare Conference to be held at the Lotte New York Palace Hotel in New York City on Wednesday, 2 December at 11:30 a.m. EST.
A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex®, which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox- Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.
CONTACT: GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations (U.S.) (Today) +44 20 3727 1000
917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries) Ben Atwell / Simon Conway
+ 44 20 3727 1000
Source: GW Pharmaceuticals plc News Provided by Acquire Media
|
distributed by
|
